Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

$Viracta Therapeutics (VIRX.US)$SAN DIEGO, Dec. 04, 2023 (GL...

$Viracta Therapeutics (VIRX.US)$SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that additional data from the Phase 1b/2 clinical trial of Nana-val (nanatinostat in combination with valganciclovir) in patients with recurrent or metastatic (R/M) Epstein-Barr virus-positive (EBV+) nasopharyngeal carcinoma (NPC) showed two ongoing confirmed partial responses (PRs) at higher dose levels. These data were featured in an oral presentation made by A. Dimitrios Colevas, M.D., Professor of Medicine (Oncology) at the Stanford Cancer Institute, during the European Society for Medical Oncology (ESMO) Asia Congress being held in Singapore. Nana-val is the company's all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
7613 Views
Comment
Sign in to post a comment
    169Followers
    870Following
    919Visitors
    Follow